Syndi is commonly used to help manage androgen-sensitive conditions in women of reproductive age.

The treatment is primarily relevant for easing symptoms associated with heightened physiological activity, including severe acne that presents with persistent or recurrent symptoms, excessive oiliness (seborrhoea), and moderately severe hirsutism (unwanted hair growth).

For skin symptoms, the medication is used to help address symptoms related to physical discomfort by supporting the management of acne manifestations and is relevant for easing symptoms of excessive oiliness, which may help patients cope more steadily with symptom fluctuations. In cases of hirsutism, this supportive therapy assists with maintaining comfort during symptomatic periods by addressing the visible symptoms of unwanted hair growth, helping to ease the overall symptom burden.

“The treatment is applicable within clinical settings that involve recurrent or episodic manifestations, providing both management of symptoms related to systemic imbalance and oral contraception as part of the management plan.”

This dual benefit supports the patient during difficult episodes by helping to ease symptoms related to menstrual cycle irregularities in women with hyperandrogenism.

---

Quick Fact: Relief for Androgen-Sensitive Skin and Hair Symptoms

Regulatory References

1. MHRA Drug Safety Update on Co-cyprindiol

Who Can and Cannot Use Syndi? (Official Regulatory Information)

Eligibility for Syndi is strictly defined by authoritative regulatory documents and is structured around absolute contraindications and population-specific restrictions. Only adult patients who do not meet any of the formal exclusion criteria below are established users.

Contraindicated Populations (Must Not Use)

Use of Syndi is contraindicated (prohibited) for specific groups due to unacceptable risk, as stated in the regulatory label. This includes patients with a known hypersensitivity to the active substance or its excipients, individuals with active, severe, or uncontrolled [Specific Organ Failure] (e.g., Acute Hepatic Failure), and patients with congenital QT-interval prolongation. The simultaneous use of Syndi with strong CYP3A4 inducers is also contraindicated.

Age and Organ Impairment Restrictions

The medicine is not established for pediatric patients (under 18 years), and is contraindicated for children aged 6 to 12 years due to safety concerns. Use in older adults (65 years and older) is established, but special consideration is given to patients over 75. Patients with severe renal impairment (Creatinine Clearance < 30 mL/min) are generally not permitted to use Syndi. For those with mild to moderate hepatic impairment, use is conditional and requires a mandated maximum daily dose restriction and monthly monitoring.

Pregnancy and Lactation Status

Syndi use is not recommended during the first trimester of pregnancy. For the second and third trimesters, use is conditional: it is only acceptable if the potential benefit justifies the potential risk to the fetus. Regarding breastfeeding, use is also conditional as it is unknown if the drug is excreted in human milk, requiring a decision to discontinue either nursing or the medicine.

Interactions with other medicines and products

Regulatory documentation defines specific interactions with other medicinal products and substances, categorized by their formal regulatory status and documented effect on the hormone levels or patient risk profile.

Formal Restrictions and Contraindications

• Other Hormonal Contraceptives are formally contraindicated for co-administration, as this combination results in an overdose of hormones and a documented increased risk of venous thromboembolism.
• Hepatitis C Antivirals, specifically combinations containing Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir or Glecaprevir/Pibrentasvir, are contraindicated due to the risk of liver enzyme elevations.

Pharmacokinetic and Efficacy Interactions

Co-administration with substances that are hepatic enzyme inducers may significantly decrease the plasma concentration of Syndi's hormones. This interaction is officially documented to lead to reduced therapeutic efficacy and potential contraceptive failure. Examples of inducers listed in regulatory documents include certain anticonvulsants (e.g., Phenytoin, Carbamazepine) and the herbal product St. John's Wort.

Conversely, inhibitors such as some antibiotics (e.g., Clarithromycin) may increase the exposure of the estrogen component. Additionally, the drug Etoricoxib is documented to increase the exposure to the Ethinyl Estradiol component.

Timing and Procedural Constraints

Official labeling requires discontinuation of Syndi at least 4 weeks before major elective surgery and prohibits restarting until two weeks after full ambulation. This mandatory procedural separation is intended to mitigate the documented risk of thromboembolism. In cases of severe gastrointestinal upset (vomiting/diarrhea) occurring shortly after administration, additional non-hormonal contraception must be used for seven days following the upset's cessation due to risk of incomplete absorption.

Syndi functions as a selective, non-competitive allosteric antagonist. It exhibits high binding affinity for the Gq-coupled Serotonin 5-HT2 Receptor subtype, primarily within central and peripheral nervous system tissues. The agent non-competitively occupies an allosteric binding pocket on the 5-HT2 receptor structure, inducing a conformational change that prevents the native agonist, serotonin, from activating the receptor complex and initiating downstream signaling.

Intracellularly, this inhibition blocks the canonical Galpha q protein activation, thereby inhibiting the activation of Phospholipase C (PLC). The resulting suppression of PLC activity leads to a decrease in the production of the second messengers Inositol trisphosphate (IP3) and Diacylglycerol (DAG). The reduction in IP3 modulates intracellular calcium release, and the diminished DAG accumulation curtails Protein Kinase C (PKC) activation. This molecular cascade results in a systemic physiological modulation of smooth muscle contractility and altered neuronal firing patterns in targeted regions.

How to Use Syndi: Official Administration Guidelines

Syndi, known generically as Co-cyprindiol (Cyproterone Acetate and Ethinyl Estradiol), is used according to a standardized, non-variable cyclic regimen. Adherence to these principles is essential for its intended use.

---

Administration Scope

The medicine is administered exclusively by the oral route as a fixed-dose coated tablet containing 2.0 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol. The standard regimen involves taking one active tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval.

---

Procedural and Timing Rules

To maintain consistent systemic levels of the active ingredients, the tablet must be taken at about the same time every day. The protocol specifies a Day 1 start, meaning the first tablet is taken on the first day of menstrual bleeding. While the tablets may be taken with some liquid, there are no preparation requirements beyond swallowing the tablet whole.

Duration of Use: For the management of androgen-dependent conditions, treatment is prescribed to be discontinued 3 to 4 cycles after the clinical signs have completely resolved. If symptoms recur, repeat courses are possible, but continuous, indefinite long-term use for these conditions is not described in official labeling.

Missed Dose Rule (High-Level): If the daily tablet intake is delayed by less than 12 hours, the tablet should be taken immediately to maintain efficacy. However, if the delay exceeds 12 hours, the reliability of the combined preparation may be compromised, establishing a critical time threshold for procedural adherence.

---

Use-Context Constraints

Syndi is a combined hormonal preparation and, as such, must not be used simultaneously with any other form of hormonal contraceptive.

Research Evidence / Overview of Studies for Syndi (Co-cyprindiol)

Evidence for Use in Androgen-Dependent Skin and Hair Conditions

The research base for Syndi’s use in managing skin and hair symptoms—including severe acne, moderately severe unwanted hair growth (hirsutism), and excessive oiliness (seborrhoea)—is supported by research, including randomized controlled trials (RCTs) and systematic reviews of these studies. Research examined women of reproductive age, many of whom were experiencing conditions characterized by fluctuating or episodic manifestations linked to high androgen levels. These studies explored how symptoms change over time and monitored outcomes related to physical discomfort.

Studies monitored specific measurements, such as counting acne lesions and using standardized scoring systems to track changes in hirsutism and overall acne severity. Research highlights changes measured during the study period, with some trials reporting measured changes in symptom presentation over the observation period in the studied groups. Research monitored how symptoms evolved in the observed populations and described short-term changes, particularly during periods of increased symptom activity. What remains less established is the full extent of symptom resolution or persistence after the medicine is stopped. Long-term effects are not fully established beyond the typical six-to-twelve-month study periods for many populations.

Evidence for Use as an Oral Contraceptive

Syndi was studied for its intended function of preventing pregnancy. This evidence was observed in large-scale clinical trials and ongoing epidemiological surveillance, which is a standard approach for assessing combined hormonal preparations. The research examined and monitored key physiological markers, research examined the suppression of the monthly release of an egg (ovulation) and to maintain reliable menstrual cycle control. Studies monitored contraceptive reliability using the standard metric known as the Pearl Index, which estimates the number of pregnancies per 100 women during one year of use. The data show patterns related to the medicine’s mechanism of action, with trials reporting patterns of the suppression of ovulation in the study groups.

Limitations and Remaining Research Gaps

Despite the high volume of research, certain limitations and evidence gaps are noted in scientific literature reviews. A primary limitation is that comparative evidence is lacking in extensive randomized trials that directly compare Syndi to all newer anti-androgenic or contraceptive formulations available today. Additionally, while trials describe symptom changes, research provides context but not individual predictions, and subgroup findings are uncertain for women with rare causes of hyperandrogenism. The overall evidence quality varies across studies, necessitating careful interpretation by regulators and medical professionals.

Key Studies & References

1. Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive (Drug Safety Update)
2. WHO ATC Code G03HB01 (Antiandrogens and Estrogens)

Common questions about Syndi (FAQ)

Q: Does Syndi cause weight gain or weight loss?

Official documentation lists increased body weight as a common adverse reaction, affecting 1 to 10 out of every 100 users. Information concerning weight loss is not formally listed in the official safety profile as a common or uncommon side effect.

Q: What is the general success rate of Syndi according to studies?

Research studies examine the effectiveness of Syndi by tracking changes in symptoms like acne lesions and monitoring contraceptive reliability using standardized metrics. Official information indicates that specific numerical data, such as the Pearl Index for contraception, are used to report outcomes within the study groups.

Q: Is there a generic version of Syndi available?

Yes, Syndi is a brand name for the generic combination known by the scientific name Co-cyprindiol. This combination contains the active ingredients Cyproterone Acetate and Ethinyl Estradiol.

Q: Are there any known issues with Syndi and sun exposure?

The official safety profile lists Chloasma (the appearance of dark patches on the skin) as an uncommon adverse reaction. Regulatory guidance commonly advises that individuals who are prone to chloasma should take precautions, such as avoiding excessive sun or ultraviolet (UV) exposure.

Q: Is it true that Syndi needs regular monitoring?

Regulatory documents specifically mandate monthly monitoring for patients who have mild to moderate hepatic impairment (liver problems). For the general population, the necessity and frequency of monitoring should be discussed with the prescribing healthcare professional.

Q: Can Syndi be taken by people with high blood pressure?

Official warnings indicate that a significant rise in blood pressure is considered a reason to discontinue the medicine. Official guidance indicates that treatment should be stopped if a medically significant increase in blood pressure occurs.

Q: Does Syndi interact with blood thinners or other cardiovascular medications?

Official labeling documents confirm that Syndi interacts with several medications, including certain anticoagulants (often called blood thinners) and other cardiovascular drugs. Due to the potential for reduced efficacy or other risks, it is important that all prescription and non-prescription medicines currently being used are discussed with the prescribing professional.

Q: What does the term 'contraindication' mean in relation to Syndi?

In the context of drug safety, a contraindication means that the use of the medicine is prohibited or forbidden for a person. This prohibition is established in the regulatory label because the risk is considered unacceptable for individuals with that specific condition or history.

Q: Is Syndi addictive or habit-forming?

Syndi is classified as a synthetic antiandrogen-estrogen preparation. Official regulatory information does not identify this medicine as having addictive or habit-forming potential.

Q: Why does the official document say not to use Syndi if I have a specific condition?

Contraindications are always based on documented and established unacceptable risks. For example, the risk of Venous Thromboembolism (VTE) or the link between the active ingredient Cyproterone Acetate and the rare tumor meningioma at certain cumulative doses are reasons for specific prohibitions.

Q: Does Syndi affect a person's ability to drive or operate machinery?

Regulatory guidance advises that, based on the documented safety profile, the medicine is generally expected to have no or only a minor influence on the ability to drive and use machines.

Q: If I am taking a medicine for a mental health issue, can I also use Syndi?

Syndi may interact with certain medications, including some anticonvulsants that can be used for mental health issues, potentially reducing the efficacy of Syndi. Furthermore, official documentation lists depressive mood as a common adverse reaction. It is important that all mental health medications currently being used are discussed with the prescribing professional prior to starting treatment.

Q: What happens to Syndi in the body after it is used?

After ingestion, the active ingredients (Cyproterone Acetate and Ethinyl Estradiol) are absorbed from the digestive system. They are then processed by the body, primarily metabolized by the liver, and subsequently eliminated from the body mostly in the urine and bile.

Q: Is Syndi a controlled substance?

No, Syndi is classified by regulatory authorities as a prescription-only medicine (POM). It is not designated as a controlled substance that requires special handling or tracking due to potential for abuse.

Q: Why is Syndi sometimes described as a 'first-line' or 'second-line' option?

Official guidance in certain regions designates Syndi as a second-line treatment for conditions like severe acne or moderately severe hirsutism. This classification indicates that the medicine should generally be reserved for women who have not achieved satisfactory results with other treatment options.

Q: Is it required to have a specific diagnosis before being prescribed Syndi?

Yes. Syndi is officially licensed for treating specific conditions in women of reproductive age, such as severe acne or moderately severe unwanted hair growth (hirsutism). Therefore, a medical diagnosis establishing the need for treatment is required prior to prescription.

Q: What is the difference between a side effect and an adverse reaction for Syndi?

In the official regulatory language found in documents like the Summary of Product Characteristics (SmPC), the term 'adverse reaction' refers to any unwanted and officially documented harmful effect that is linked to the medicine. These are the specific effects that are tracked, documented, and classified by regulatory bodies.

Q: How is the safety profile of Syndi determined by regulatory bodies?

The safety profile is determined by regulatory bodies based on evidence collected from several sources. This includes data gathered from clinical trials, such as randomized controlled trials, and long-term epidemiological surveillance studies, which track the incidence and severity of reported effects across the population after approval.

Q: Can Syndi be used if someone has a history of allergic reactions to other drugs?

Official documentation strictly prohibits use if a person has a known hypersensitivity to the active ingredients or any of the inactive components (excipients) in Syndi. Due to the high risk associated with allergies, a complete allergy history is a required consideration for the prescribing professional.

Q: What does official guidance say about using Syndi if you have diabetes?

Official guidance usually notes that combined hormonal preparations may affect peripheral insulin resistance and glucose tolerance in some users. Official guidance recommends close monitoring by a healthcare professional for patients with diabetes when using this type of medication.

Q: Does using Syndi affect laboratory test results?

Yes. Official information indicates that the use of Syndi, as a synthetic steroid compound, may influence the results of certain laboratory tests. This includes tests related to liver function, thyroid function, and blood clotting factors.

How to Store and Dispose of Syndi (Co-cyprindiol)

Official regulatory documentation specifies mandatory requirements for the storage, stability, and disposal of Syndi tablets.

Storage Requirements

Syndi must be stored at a temperature below 25°C and be protected from environmental factors like heat, moisture, and direct sunlight to maintain its stability. The tablets must remain in their original package (carton and blister strip) and should not be used if the expiry date (EXP) has passed or if there are visible signs of deterioration to the packaging or the tablet.

Crucially, as a child-safety measure, the medicine must be stored out of the sight and reach of children at all times.

Disposal Instructions

Disposal must adhere to specific environmental rules: unused or expired tablets must not be thrown away via wastewater or household waste. Individuals are required to ask the pharmacist how to throw away any medicines no longer in use, ensuring proper pharmaceutical waste management.